Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic AKR
Time: 16:30:10
Mid Price: 12.25
Change Today: 0.00
Change % Today: 0.00
Fifty Two Week High: 27.00
Fifty Two Week Low: 11.25
Market Capital: 14.01
Period & price data
Period Price
Now: 12.25
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Healthcare, Equipment & Services
Epic: AKR
News: Latest news
Web Site: Akers Biosciences
Other Articles:

Akers Biosciences

Akers Biosciences, Inc. (ABI) is engaged in designing, manufacturing and marketing vitro diagnostic products. The Company’s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time-sensitive therapeutic decisions.
Monday, January 05, 2009

Akers Biosciences sells breath test product rights

company news image


Akers Biosciences Inc said it sold the intellectual property pertaining to the Free Radical Enzymatic Device (FRED) and future non-invasive exhaled breath test technology to Pulse Health LLC, based in Oregon, for US$3 million in cash.


The AIM-listed designer and manufacturer of rapid diagnostic screening and testing products said it will further benefit from an exclusive manufacturing agreement to supply FRED Aldehyde Assay Tubes at a price fixed for three years and also earn a per tube royalty fee for every FRED Aldehyde Assay Tube sold over that period.  


In addition, ABI has the possibility to extend the exclusive manufacturing agreement beyond the initial 3-year term and Pulse has agreed to fund any future R&D projects that ABI undertakes on their behalf.
Notwithstanding the Agreement, ABI will retain the rights related to and solely own certain other tests incorporating non-invasive exhaled breath test technology, namely the BreathScan Alcohol Detector, the Legal Limit POV Safety Keychain, the Breath Alcohol Check .02 Detection System, the Breath Ketone Check and the Breath PulmoHealth Check


Pulse was formed to investigate new opportunities to market health and wellness evaluation devices. In 2006, Pulse approached Akers with the challenge of applying the company's patented breath condensate technology to develop a breath detection system to measure free radical activity in the body. The project, funded by Pulse, was extremely successful and led to the creation of FRED, the first non-invasive, easy-to-use test that helps monitor levels of free radicals and assess the effectiveness of nutritional supplements in the human body.

NewsNow icon AddThis Feed Button
Register here to be notified of future Akers Biosciences articles.

Investors interested in Akers Biosciences recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.